Phase II study of panitumumab with irinotecan as third-line treatment for advanced colorectal cancer patients

ABSTRACT: Interventions: Panitumumab+CPT-11 repeat every 14 days until discontinuance criteria. Primary outcome(s): Response Rate:RR Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2620620 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR